Company research
Protalix BioTherapeutics, Inc.
CIK 1006281Updated Sep 26, 2026
SecurityPLX · NYSE_AMERICAN · equity
Name history
ORTHODONTIX INC · through Feb 22, 2007EMBASSY ACQUISITION CORP · through Mar 31, 1998
PLX price & chart
Loading TradingView…
AMEX:PLX on TradingView ↗About the company
Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are currently available in multiple markets. These therapies are recombinant therapeutic proteins expressed through Protalix’s proprietary plant cell-based expression system, ProCellEx®. ProCellEx is a unique plant cell-based system that enables Protalix to produce recombinant proteins in an industrial-scale manner with no exposure to mammalian cells. Protalix is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa, Elelyso®, for the treatment of Gaucher disease, excluding in Brazil where Protalix retains full rights.
In the news
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC News provided by Protalix BioTherapeutics, Inc. May 14, 2025, 06:50 ET Share this article Share to X Share this article Share to X CARMIEL, Israel , May 14, 2025 /PRNewswire/ -- Protali ↗
Seeking Alpha
Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
Protalix signals Elfabrio path to 15% to 20% Fabry market share by 2031, backed by Europe every-4-weeks approval ↗
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript ↗
Recent filings
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G filing
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
ARS filing
DEF 14A filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 82,346,000Source | 73,417,000Source | 84,434,000Source | 55,787,000Source |
| Property, Plant and Equipment, NetUSD | 4,879,000Source | 4,591,000Source | 4,973,000Source | 4,553,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 14,680,000Source | 19,760,000Source | 23,634,000Source | 17,111,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 8,840,000Source | 2,909,000Source | 5,272,000Source | 4,586,000Source |
| Inventory, NetUSD | 25,729,000Source | 21,243,000Source | 19,045,000Source | 16,804,000Source |
| Assets, CurrentUSD | 66,673,000Source | 60,078,000Source | 69,932,000Source | 44,880,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,700,000Source | 5,430,000Source | 5,909,000Source | 5,087,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 34,116,000Source | 30,206,000Source | 50,865,000Source | 66,427,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 80,000Source | 76,000Source | 73,000Source | 54,000Source |
| Retained Earnings (Accumulated Deficit)USD | -384,997,000Source | -378,393,000Source | -381,549,000Source | -389,861,000Source |
| Stockholders' Equity Attributable to ParentUSD | 48,230,000Source | 43,211,000Source | 33,569,000Source | -10,640,000Source |
| Additional Paid in Capital, Common StockUSD | 433,147,000Source | 421,528,000Source | 415,045,000Source | 379,167,000Source |
| Liabilities and EquityUSD | 82,346,000Source | 73,417,000Source | 84,434,000Source | 55,787,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 26,518,000Source | 25,621,000Source | 45,530,000Source | 32,429,000Source |
| Operating Lease, Liability, CurrentUSD | 1,384,000Source | 1,500,000Source | 1,409,000Source | 1,118,000Source |
| Accounts Payable, CurrentUSD | — | — | 19,550,000Source | 12,271,000Source |
| Operating Lease, Liability, NoncurrentUSD | 6,937,000Source | 4,026,000Source | 4,621,000Source | 4,169,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 9,790,000Source | 9,568,000Source | 9,009,000Source | 8,008,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -6,604,000Source | 2,932,000Source | 8,312,000Source | -14,927,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,297,000Source | 3,253,000Source | 3,448,000Source | 2,085,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 5,890,000Source | -2,317,000Source | 428,000Source | 1,194,000Source |
| Increase (Decrease) in InventoriesUSD | 4,486,000Source | 2,198,000Source | 2,241,000Source | -1,150,000Source |
| Deferred Income Tax Expense (Benefit)USD | 340,000Source | 236,000Source | -3,092,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -11,993,000Source | 8,674,000Source | -1,318,000Source | -25,000,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -2,366,000Source | 4,221,000Source | -16,711,000Source | -5,035,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | 26,000Source | -80,000Source | 142,000Source | -593,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,638,000Source | 1,282,000Source | 1,149,000Source | 628,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 9,326,000Source | -16,794,000Source | 24,666,000Source | 8,238,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -5,080,000Source | -3,874,000Source | 6,523,000Source | -21,874,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 14,680,000Source | 19,760,000Source | 23,634,000Source | 17,111,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 1,532,000Source | 2,742,000Source | 2,198,000Source |
| Income Taxes Paid, NetUSD | 1,183,000Source | 385,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,297,000Source | 3,253,000Source | 3,448,000Source | 2,085,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 0Source | 0Source | 267,000Source | 300,000Source |
| DepreciationUSD | 1,465,000Source | 1,304,000Source | 1,191,000Source | 1,086,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -606,000Source | -310,000Source | 446,000Source | 989,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 0Source | 3,000Source | -9,000Source | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 996,000Source | 1,222,000Source | 254,000Source | 530,000Source |
| Inventory Write-downUSD | 30,000Source | 90,000Source | 800,000Source | 40,000Source |
| Net Income (Loss) Attributable to ParentUSD | -6,604,000Source | 2,932,000Source | 8,312,000Source | -14,927,000Source |
| Nonoperating Income (Expense)USD | -108,000Source | 237,000Source | -1,894,000Source | -1,383,000Source |
| Proceeds from Issuance of Common StockUSD | 6,812,000Source | 3,626,000Source | 23,954,000Source | 8,236,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 52,744,000Source | 53,399,000Source | 65,494,000Source | 47,638,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 11,682,000Source | 12,193,000Source | 14,959,000Source | 11,711,000Source |
| Operating Income (Loss)USD | -5,500,000Source | 3,917,000Source | 10,460,000Source | -13,014,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -5,608,000Source | 4,154,000Source | 8,566,000Source | -14,397,000Source |
| Income Tax Expense (Benefit)USD | 996,000Source | 1,222,000Source | 254,000Source | 530,000Source |
| Net Income (Loss) Attributable to ParentUSD | -6,604,000Source | 2,932,000Source | 8,312,000Source | -14,927,000Source |
| Earnings Per Share, BasicUSD per share | -0.08Source | 0.04Source | 0.12Source | -0.31Source |
| Earnings Per Share, DilutedUSD per share | -0.08Source | 0.04Source | 0.09Source | -0.31Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 78,546,234Source | 72,530,698Source | 67,512,527Source | 48,472,159Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 78,546,234Source | 81,057,176Source | 82,424,016Source | 48,472,159Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 656,000Source | 986,000Source | 3,346,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -4,579,000Source | — | — | — |
| Labor and Related ExpenseUSD | — | 21,780,000Source | — | — |
| Nonoperating Income (Expense)USD | -108,000Source | 237,000Source | -1,894,000Source | -1,383,000Source |
| Research and Development ExpenseUSD | 19,569,000Source | 12,970,000Source | 17,093,000Source | 29,349,000Source |
Filing attachments
plx-20260812xex99d1.htm · 8-K · 2026-08-12
EX-99.1 2 plx-20260812xex99d1.htm EX-99.1 Exhibit 99.1 Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio® Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, whic…
Read attachment ↗plx-20260521xex99d1.htm · 8-K · 2026-05-21
EX-99.1 2 plx-20260521xex99d1.htm EX-99.1 Exhibit 99.1 1 PROTALIX BIOTHERAPEUTICS C O R P O R A T E P R E S E N T A T I O N J u n e 2024 PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases C O R P O R A T E P R E S E N T A T I O N M a y 2026 2 Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties within the meaning of Section 27A of the Securities Act of 1933, as am…
Read attachment ↗plx-20260513xex99d1.htm · 8-K · 2026-05-13
EX-99.1 2 plx-20260513xex99d1.htm EX-99.1 Exhibit 99.1 Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every-4-weeks (E4W) dosing regimen; $25 million milestone received from Chiesi PRX-115 Phase 2 study continues to advance as planned with top-line results anticipated in the second half o…
Read attachment ↗plx-20260318xex99d1.htm · 8-K · 2026-03-18
EX-99.1 2 plx-20260318xex99d1.htm EX-99.1 Exhibit 99.1 Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® in adults living with Fabry disease providing a meaningful reduction in treatment burden without compromising efficacy The EC approval triggered the Company’s entitlement to a $25.0 mil…
Read attachment ↗plx-20260309xex99d1.htm · 8-K · 2026-03-09
EX-99.1 2 plx-20260309xex99d1.htm EX-99.1 Exhibit 99.1 Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for Elfabrio is not approved in the US. In the US, the FDA-approved dosing regimen remains 1mg/kg every 2 weeks. Please see …
Read attachment ↗plx-20260211xex99d1.htm · 8-K · 2026-02-11
EX-99.1 2 plx-20260211xex99d1.htm EX-99.1 1 PROTALIX BIOTHERAPEUTICS C O R P O R A T E P R E S E N T A T I O N J u n e 2024 PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases C O R P O R A T E P R E S E N T A T I O N F e b r u a r y 2026 Exhibit 99.1 2 Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties within the meaning of Section 27A of the Securities Act of …
Read attachment ↗